

DNA METHYLATION AND COPY NUMBER
VARIATION OF THE COMPLEMENT C4A AND CUB
AND SUSHI MULTIPLE DOMAINS 1 GENES IN
SCHIZOPHRENIA PATIENTS AND HEALTHY
CONTROLS

BY

MOHD ASYRAF BIN ABDULL JALIL

A thesis submitted in fulfillment of the requirement for the
degree of Doctor of Philosophy in Health Sciences

Kulliyyah of Medicine
International Islamic University of Malaysia

FEBRUARY 2023

ABSTRACT

Schizophrenia is a chronic and disabling mental illness with unknown cause and incompletely understood pathogenesis. Evidence from genome-wide association studies (GWAS) and experimental studies had suggested the role of two immune related proteins, the complement C4, coded partly by the *C4A* gene, and the CUB and Sushi Multiple Domains 1 (*CSMD1*). However, there was no available report on the association between schizophrenia and DNA methylation of the *C4A* and *CSMD1* genes. Such study is important because DNA methylation is a modifiable factor that can affect candidate genes' expression and therefore explain the genetic-environment interaction in schizophrenia's pathogenesis. Both genes also have copy number variation (CNV) which can influence gene expression. This study aims to compare the DNA methylation level and the copy number of *C4A* and *CSMD1* genes between schizophrenia patients and healthy controls, and to evaluate their relationship with schizophrenia psychopathology. A total of 183 schizophrenia patients and 212 healthy controls were included in this comparative cross-sectional study. DNA methylation levels and gene copy number were determined from peripheral blood samples using MethyLight™ analysis and droplet digital polymerase chain reaction (ddPCR) respectively. C4 plasma levels was measured using immunoturbidimetry. Psychopathological data of patients were measured using the Positive and Negative Syndrome Scale (PANSS) and the Personal and Social Performance (PSP) scale. Plasma C4 levels were found to be significantly higher in schizophrenia patients compared to controls ($p < 0.001$). While *C4A* DNA methylation levels and copy number were both positively correlated with plasma C4 levels ($p < 0.001$), there was no significant difference in the two variables between patients and controls. The DNA methylation levels of *CSMD1* were significantly lower in schizophrenia patients compared to healthy controls ($p = 0.001$), but its copy number did not differ significantly between the groups. *C4A* deletion and higher *CSMD1* DNA methylation levels were also associated with lesser positive symptom severity ($p = 0.027$). In multivariate analysis, both *CSMD1* DNA methylation levels and plasma C4 levels were significant predictors for schizophrenia. Overall, the results suggested the potential involvement of DNA methylation of *C4A* and *CSMD1* in schizophrenia pathophysiology, particularly in pathways relevant to the positive symptoms. Since DNA methylation may be reversed, this could be a useful target in for the development of new treatment in the future. Further studies are required to identify the underlying mechanism for these findings.

ملخص البحث

الفصام هو مرض عقلي مزمن ومسبب للإعاقة ومجهول السبب ولم يعرف سبب تطوره بشكل كامل. اقترحت الأدلة من دراسات الترابط الجينومي الكامل (GWAS) والدراسات التجريبية دور بروتينين مرتبطين بالمناعة، أولهما عامل جملة المتممة C4، الذي يشفر جزئيًا بواسطة جين *C4A* و *CUB* و *Sushi Multiple Domains 1* (*CSMD1*). و لكن لم يوجد هناك تقرير عن العلاقة بين الفصام و مثيلة الحمض النووي لجينين *C4A* و *CSMD1*. الدراسة مثلها مهمة لأن مثيلة الحمض النووي هي عامل قابل للتعديل يمكن أن يؤثر على تعبير الجينات المرشحة وبالتالي يفسر التفاعل بين البيئة والجينات في تطور الفصام. يحتوي كلا الجينين أيضًا على اختلاف في عدد النسخ الذي يمكن أن يؤثر على التعبير الجيني أيضًا. تهدف هذه الدراسة إلى مقارنة مستوى مثيلة الحمض النووي وعدد نسخ الجينين *C4A* و *CSMD1* بين مرضى الفصام والضوابط الصحية ، وتقييم علاقتهم ببيكوباثولوجيا للفصام. تم تضمين ما مجموعه 183 مريضًا بالفصام و 212 من الأصحاء في هذه الدراسة المستعرضة المقارنة. تم تحديد مستويات مثيلة الحمض النووي وعدد نسخ الجين من عينات الدم الطرفية باستخدام تحليل ميثي لايت (MethyLight™) وتفاعل البلمرة المتسلسل الرقمي للقطيرات (ddPCR) على التوالي. تم قياس مستويات C4 في البلازما باستخدام مقياس كدر المناعة. تم قياس البيانات السيکوباثولوجية للمرضى باستخدام مقياس المتلازمة الإيجابية والسلبية (PANSS) ومقياس الأداء الشخصي والاجتماعي (PSP). تم العثور على مستويات البلازما C4 لتكون أعلى بشكل ملحوظ في مرضى الفصام مقارنة بالضوابط ($p < 0.001$). بينما كان كل من مستويات مثيلة الحمض النووي لـ *C4A* وعدد نسخه مرتبطين بشكل إيجابي مع مستويات C4 في البلازما ($p < 0.001$)، لم يكن هناك فرق واضح في

هذين المتغيرين بين المرضى والضوابط. كانت مستويات مثيلة الحمض النووي لـ *CSMD1* أقل بشكل ملحوظ في مرضى الفصام مقارنة بالضوابط الصحية ($p = 0.001$) ، لكن عدد نسخه لم يختلف بشكل واضح بين المجموعتين. وأيضًا، ارتبط حذف *C4A* وأعلى مستويات مثيلة الحمض النووي لـ *CSMD1* مع أقل حدة أعراض إيجابية ($p = 0.027$). في التحليل متعدد المتغيرات ، كان كل من مستويات مثيلة الحمض النووي لـ *CSMD1* ومستويات *C4* في البلازما تنبأ مهمًا للفصام. بشكل عام ، اقترحت النتائج المشاركة المحتملة لميثيل الحمض النووي لـ *C4A* و *CSMD1* في الفسيولوجيا المرضية للفصام، لا سيما في المسارات ذات الصلة بالأعراض الإيجابية. نظرًا لأنه قد يتم عكس مثيلة الحمض النووي ، يكون هذا مفيدًا في التفكير في تطوير علاج جديد في المستقبل. هناك حاجة إلى مزيد من الدراسات لتحديد الآلية الكامنة وراء هذه النتائج.

APPROVAL PAGE

The thesis of Mohd Asyraf Bin Abdull Jalil has been approved by the following:



Norlelawati A Talib
Supervisor



Nour El Huda Abd Rahim
Co-Supervisor

Norafiza Zainuddin
Internal Examiner

Edinur Hisham Atan
External Examiner


Mohd Zulfaezal Che Azemin
Chairman

DECLARATION


I hereby declare that this thesis is the result of my own investigation, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Mohd Asyraf Bin Abdull Jalil

Signature



Date16/2/2023.....



INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH**

**DNA METHYLATION AND COPY NUMBER VARIATION OF
THE COMPLEMENT C4A AND CUB AND SUSHI MULTIPLE
DOMAINS 1 GENES IN SCHIZOPHRENIA PATIENTS AND
HEALTHY CONTROLS**

I declare that the copyright holder of this thesis is International Islamic University Malaysia.


Copyright © 2023 International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may only be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purpose.
3. The IIUM library will have the right to make, store in a retrieval system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Mohd Asyraf Bin Abdull Jalil



Signature

16/2/2023

Date



*I dedicated this thesis to all mental illness sufferers. May there be light at the end of
your tunnels.*

ACKNOWLEDGEMENTS

All praises to Allah the most benevolent and the most merciful, for all that He has provided me with in this life. It is only by His mercy and permission that this effort would finally succeed.

I express my sincere gratitude to my supervisor, Assoc. Prof. Dr. Norlelawati A Talib for the guidance, assistance, patience, and wisdom that she had shared with me during this academic journey. I extend this same gratitude to Dr. Norsidah Ku Zaifah, Dr. Hanisah Mohd Noor and Asst. Prof. Dr. Nour El Huda Abd Rahim for giving their full support whenever needed. Thanks to all lecturers who had offered constructive inputs during this study.

I would like to thank the Deputy Dean for Postgraduate and Research and everyone at the Kulliyyah of Medicine's Postgraduate Office for good management of my PhD journey from start to finish. I appreciate the assistance given by the Head and everyone at the Department of Basic Medical Sciences, KOM and Department of Pathology and Laboratory Medicine, SASMEC. Thanks to all laboratory staff members who had assisted with technical aspects and to fellow postgraduate students who had given assistance and encouragement. A special mention to Dr Noorul Amilin Harun and her awesome team at the Department of Psychiatry and Mental Health, Hospital Tengku Ampuan Afzan Kuantan.

Lots of love and gratitude to my wife and daughters. Thank you for being patient and understanding. Not to forget my parents, as well as my siblings cum guarantors - thank you.

Finally, thanks to all the kind and helpful ladies and gentlemen who had consented to participate in this study. To those I have yet to acknowledge, I can only say thank you.

To everyone above, I will always be indebted to you. May you always be in good health and circumstances.

TABLE OF CONTENTS

Abstract	ii
Abstract in Arabic	iii
Approval Page.....	v
Declaration.....	vi
Copyright	vii
Acknowledgements.....	ix
List of Tables	xv
List of Figures	xviii
List of Abbreviations / Symbols	xxi

CHAPTER ONE: INTRODUCTION 1

1.1 Background of the Study	1
1.2 Problem Statement	5
1.3 Research Question	7
1.4 Research Objectives	8
1.4.1 General Objective.....	8
1.4.2 Specific Objectives.....	8
1.5 Research Hypotheses	8
1.6 Justification and Rationale of The Study	9

CHAPTER TWO: LITERATURE REVIEW..... 11

2.1 Schizophrenia.....	11
2.1.1 Epidemiology	11
2.1.2 Disease Burden.....	12
2.1.3 Clinical Features.....	14
2.1.4 Positive and Negative Syndrome Scale (PANSS)	17
2.1.5 Antipsychotics and Other Therapeutic Options	20
2.1.6 Aetiology.....	24
2.2 Theory of Schizophrenia Pathogenesis	24
2.2.1 Neurochemistry Theory	25
2.2.2 Neurodevelopmental Theory.....	28
2.2.3 Infectious and Immune Theory	30
2.2.4 Genetic Theory	32
2.2.5 Psychosocial Theory	34
2.3 Immunology of Schizophrenia.....	35
2.3.1 Alterations in Immune System Balance	36
2.3.2 Kynurenine Pathway	37
2.3.3 Complement Pathways.....	40
2.4 Complement C4A and CSMD1	42
2.4.1 The Complement System	42
2.4.2 Complement C4 Genes	45
2.4.3 C4A and Schizophrenia	47
2.4.4 CSMD1 and Schizophrenia	48
2.5 DNA Methylation in Schizophrenia	50

2.5.1	Epigenetics and DNA Methylation	50
2.5.2	Epigenetics and DNA Methylation in Schizophrenia	52
2.5.3	Methods to Measure DNA Methylation.....	53
2.6	Copy Number Variation in Schizophrenia.....	57
2.6.1	Copy Number Variation.....	57
2.6.2	Genes with Copy Number Variation in Schizophrenia.....	57
2.6.3	Methods to Measure Copy Number Variation	58
2.7	Conceptual Framework	64
CHAPTER THREE: METHODOLOGY.....		66
3.1	Study Design	66
3.2	Inclusion and Exclusion Criteria.....	66
3.2.1	Inclusion Criteria for Schizophrenia Patients	66
3.2.2	Exclusion Criteria for Schizophrenia Patients	67
3.2.3	Inclusion Criteria for Healthy Controls.....	67
3.2.4	Exclusion Criteria for Healthy Controls	67
3.3	Sample Size Measurement	67
3.4	Sample and Data Collection.....	68
3.4.1	Sociodemographic Data Collection	69
3.4.2	Anthropometric Data Collection	69
3.4.3	Clinical and Psychopathological Assessment	70
3.4.4	Venous Blood Sample Collection	70
3.5	Complement Markers and C-Reactive Protein measurement	71
3.6	DNA Purification	71
3.6.1	DNA Purification, Quantification, and Purity Determination .	71
3.6.1.1	Reagent Preparation for DNA Purification.....	71
3.6.1.2	DNA Purification Steps	72
3.6.1.3	DNA Quantification and Purity Assessment Steps	73
3.6.2	DNA Integrity Assessment	73
3.7	DNA Methylation Level Measurement of <i>C4A</i> and <i>CSMD1</i>	74
3.7.1	Bisulfite Conversion	74
3.7.2	Primer and Probe Design	76
3.7.3	MethyLight™ qPCR Assay Optimisation	80
3.7.3.1	Annealing Temperature Optimisation	80
3.7.3.2	Assay Sensitivity and Efficiency	81
3.7.3.3	Assay Specificity Evaluation.....	83
3.7.4	MethyLight™ Assay for Measurement of DNA Methylation Levels	84
3.8	Genes Copy Number Determination.....	86
3.8.1	Primer and Probe Design	87
3.8.2	Optimisation of ddPCR for Copy Number Determination	88
3.8.2.1	Selection of Optimal Annealing Temperature	88
3.8.2.2	Selection of Optimal Reaction Component Concentration and DNA Template Digestion Method	90
3.8.2.3	Selection of Optimal Restriction Enzyme Digestion Method.....	93
3.8.3	Droplet Digital PCR Assay for Copy Number Determination	94
3.9	Gene Expression Study	95

3.9.1	Selection of Genes for Expression Study.....	95
3.9.2	Selection of Samples	96
3.9.3	Ribonucleic Acid Purification.....	96
3.9.4	Assessment of RNA Purity and Concentration.....	97
3.9.5	Assessment of RNA Integrity	98
3.9.6	Complementary DNA Synthesis	99
3.9.7	Primer Design	100
3.9.8	Annealing Temperature Optimisation.....	100
3.9.9	qPCR Assay Sensitivity and Efficiency Evaluation.....	102
3.9.10	qPCR Assay for mRNA Levels	103
3.10	Statistical Analyses	104
3.11	Study Flow Chart	104

CHAPTER FOUR: RESULTS 106

4.1	Subject Sociodemographic Characteristics.....	106
4.1.1	Sociodemographic and Anthropometric Characteristics of Study Groups	106
4.2	Optimisation of MethyLight™ Assay	107
4.2.1	Optimal MethyLight™ Annealing Temperature	107
4.2.2	MethyLight™ Assay Sensitivity and Efficiency	109
4.2.3	MethyLight™ Assay Specificity.....	110
4.3	Optimisation of ddPCR Copy Number Assay	111
4.3.1	Optimal ddPCR Copy Number Assay Annealing Temperature ..	111
4.3.2	Optimal ddPCR Component Concentrations and DNA Digestion Method.....	113
4.3.3	Timing for Enzyme Digestion of DNA Template.....	114
4.4	Levels of Complement C3, Complement C4 and CRP.....	115
4.4.1	Relationship between Plasma C3, C4 and CRP	117
4.4.2	Association of Sociodemographic Characteristics with Plasma C3, C4 and CRP Status	118
4.5	DNA Methylation and Copy Number Variation of <i>C4A</i>	119
4.5.1	DNA Methylation of <i>C4A</i>	119
4.5.1.1	Association of <i>C4A</i> PMR Values with Schizophrenia	119
4.5.1.2	Association of <i>C4A</i> PMR Values with Sociodemographic Factors and Body Mass Index....	120
4.5.2	Copy Number Variation of <i>C4A</i>	121
4.5.2.1	Association of <i>C4A</i> Copy Number Variation with Schizophrenia	121
4.5.2.2	Association of Sociodemographic Factors with <i>C4A</i> Copy Number Variation	123
4.6	Multivariate Analyses for <i>C4A</i> Parameters.....	123
4.7	DNA Methylation and Copy Number Variation of <i>CSMD1</i>	126
4.7.1	<i>CSMD1</i> DNA Methylation.....	126
4.7.1.1	Association of <i>CSMD1</i> PMR Values with Schizophrenia	126
4.7.1.2	Association of <i>CSMD1</i> PMR Values with Sociodemographic Factors and BMI	127
4.7.2	Copy Number Variation of <i>CSMD1</i>	129

4.8	Gene Expression Study	130
4.8.1	RNA Integrity	130
4.8.2	Optimisation of qPCR Assay for Gene Expression Study	131
4.8.2.1	Optimal Annealing Temperature	131
4.8.2.2	qPCR Assay Efficiency	132
4.9	Multivariate Analyses for <i>CSMD1</i> Parameters	136
4.10	Multivariate Analyses of All Significant Variables	136
4.11	Clinical and Psychopathological Characteristics	138
4.11.1	Relationship between Clinical-Psychopathological Characteristics and Sociodemographic Characteristics	139
4.11.2	Relationship of Clinical-Psychopathological Characteristics with Plasma C3, C4 and CRP	141
4.11.3	Relationship of Clinical-Psychopathological Characteristics with DNA Methylation and Copy Number Variation of <i>C4A</i> and <i>CSMD1</i>	141
CHAPTER FIVE: DISCUSSION		144
5.1	Overview of the Study	144
5.2	Sociodemographics and Body Mass Index	145
5.3	Levels of Plasma C3, C4 and CRP	146
5.4	DNA Methylation and Copy Number of <i>C4A</i>	149
5.5	DNA Methylation and Copy Number of <i>CSMD1</i>	153
5.6	Multivariate Analyses of All Significant Variables	157
5.7	Clinical and Psychopathological Characteristics	157
5.7.1	Justification for Recording Clinical and Psychopathological Characteristics	157
5.7.2	Summary of Clinical-Psychopathological Characteristics	158
5.7.3	Discussion on the Relationship between Clinical-Psychopathological Characteristics and Sociodemographic Characteristics	160
5.7.4	Discussion on the Relationship of Clinical-Psychopathological Characteristics with Plasma C3, C4 and CRP	161
5.7.5	Discussion on the Relationship of Clinical-Psychopathological Characteristics with DNA Methylation and Copy Number Variation of <i>C4A</i> and <i>CSMD1</i>	164
5.8	Limitations	166
5.9	Significance and Clinical Implications	168
CHAPTER SIX: CONCLUSION		169
6.1	Conclusion	169
6.2	Suggestions for Future Studies	169
REFERENCES		171
APPENDIX A: ETHICAL APPROVAL (IIUM RESEARCH ETHICS COMMITTEE)		222
APPENDIX B: ETHICAL APPROVAL (MEDICAL RESEARCH & ETHICS COMMITTEE)		224

APPENDIX C: RESEARCH APPROVAL (KULLIYYAH RESEARCH COMMITTEE)	226
APPENDIX D: PARTICIPANT INFORMATION SHEET (MALAY)	227
APPENDIX E: CONSENT FORM (MALAY).....	234
APPENDIX F: CASE RECORD FORM (PATIENT)	236
APPENDIX G: POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) FORM.....	243
APPENDIX H: PERSONAL AND SOCIAL PERFORMANCE (PSP) SCALE FORM.....	244
APPENDIX I: CASE RECORD FORM (HEALTHY CONTROL).....	245
APPENDIX J: DNA INTEGRITY EVALUATION	249
APPENDIX K: PUBLICATION & PRESENTATION	250
APPENDIX L: OTHER AWARDS.....	257



LIST OF TABLES

Table 2.1	Sign and symptom items evaluated in the PANSS.	18
Table 2.2	PANSS items rearrangement into five domains as suggested by van der Gaag et al. (2006).	19
Table 2.3	Comparison of bisulfite-conversion-based methods for evaluation of DNA methylation of a candidate gene.	55
Table 2.4	Comparison of methods to evaluate CNV at a target locus.	61
Table 3.1	Sociodemographic data collected from the study participants.	69
Table 3.2	The primer and probe sequences used in the MethyLight™ qPCR assays.	77
Table 3.3	Reaction components for MethyLight™ annealing temperature optimisation.	80
Table 3.4	Thermal cycling protocol for MethyLight™ annealing temperature optimisation.	81
Table 3.5	Reaction components for MethyLight™ sensitivity and efficiency evaluation.	82
Table 3.6	Thermal cycling protocol for MethyLight™ sensitivity and efficiency evaluation.	82
Table 3.7	Preparation of serial dilutions of DNA samples for evaluation of MethyLight™ qPCR assay specificity.	83
Table 3.8	Reaction components for MethyLight™ qPCR assay specificity evaluation.	84
Table 3.9	Thermal cycling protocol for MethyLight™ qPCR assay specificity evaluation.	84
Table 3.10	Reaction components for MethyLight™ reaction.	85
Table 3.11	Thermal cycling protocol for MethyLight™ reaction.	85
Table 3.12	Pre-designed TaqMan™ Copy Number Assays used for determination of copy number of the target genes.	88
Table 3.13	Reaction components for ddPCR assay annealing temperature optimisation.	89
Table 3.14	Thermal cycling protocol for ddPCR assay annealing temperature optimisation.	89

Table 3.15	The 16 different combinations of reagent concentration and digestion methods evaluated for ddPCR assay optimisation.	92
Table 3.16	Details of the different reagent concentration evaluated for a 24 µl reaction volume of ddPCR assay.	92
Table 3.17	Thermal cycling protocol for ddPCR reagent and template optimisation.	93
Table 3.18	Reaction components for ddPCR with DNA template digestion during the ddPCR.	94
Table 3.19	Sequences of the primer assays used in the gene expression study.	100
Table 3.20	Reaction components for gene expression study's annealing temperature optimisation.	101
Table 3.21	Thermal cycling protocol for annealing temperature optimisation of gene expression study qPCR.	101
Table 3.22	Reaction components for gene expression study's qPCR sensitivity and efficiency evaluation.	102
Table 3.23	Thermal cycling protocol for gene expression study's qPCR sensitivity and efficiency evaluation.	103
Table 4.1	Sociodemographic characteristics of subject groups.	107
Table 4.2	Quantification cycle (C _q) values for <i>C4A</i> , <i>CSMD1</i> , and <i>Alu</i> in the MethyLight™ assay across the temperature gradient.	108
Table 4.3	Association of <i>C4A</i> PMR values with sociodemographic factors and BMI.	121
Table 4.4	<i>C4A</i> copy number distribution for all subjects, schizophrenia patients and healthy controls.	122
Table 4.5	<i>C4A</i> copy number distribution among male and female subjects, as well as among Malay and Chinese subjects.	123
Table 4.6	Multiple linear regression to show relationship of <i>C4A</i> PMR values, <i>C4A</i> copy number, plasma C3 levels, CRP status, ethnicity, and BMI with C4 levels.	125
Table 4.7	Binomial logistic regression to evaluate relationship of <i>C4A</i> PMR values, <i>C4A</i> CNV and C4 levels with schizophrenia.	126
Table 4.8	Association of <i>CSMD1</i> PMR values with sociodemographic factors and BMI.	128

Table 4.9	<i>CSMD1</i> CNV in different subject groups.	130
Table 4.10	Binomial logistic regression to assess relationship <i>CSMD1</i> PMR values and <i>CSMD1</i> deletion with schizophrenia.	136
Table 4.11	Binomial logistic regression to assess relationship of plasma C3 levels, plasma C4 levels, elevated CRP, <i>CSMD1</i> PMR values and smoking with and schizophrenia.	138
Table 4.12	Relationship between psychopathology scores and sociodemographic characteristics.	140
Table 4.13	Relationship between psychopathology scores and <i>C4A</i> or <i>CSMD1</i> CNV and PMR values.	143




LIST OF FIGURES

Figure 2.1	The kynurenine pathway.	38
Figure 2.2	A schematic diagram showing the three complement pathways.	44
Figure 2.3	Examples of copy number variations of <i>C4</i> genes at the RCCX module.	46
Figure 2.4	The theoretical framework underlying this study.	64
Figure 2.5	The conceptual framework for this study.	65
Figure 3.1	Sample size calculation using OpenEpi.	68
Figure 3.2	Flow of <i>C4A</i> and <i>CSMD1</i> DNA methylation level measurement method.	74
Figure 3.3	Location of the <i>C4A</i> MethyLight™ primer and probe sequences on the short arm of chromosome 6.	78
Figure 3.4	Location of the <i>CSMD1</i> MethyLight™ primer and probe sequences on the short arm of chromosome 8.	79
Figure 3.5	Preparation of serial dilutions of DNA samples for evaluation of reaction sensitivity and efficiency.	81
Figure 3.6	Steps in determination of <i>C4A</i> and <i>CSMD1</i> gene copy number.	87
Figure 3.7	Standard workflow for gene CNV determination using ddPCR.	90
Figure 3.8	Flow of the gene expression study.	95
Figure 3.9	Flow chart of the methodology used in this study.	105
Figure 4.1	Amplification curves for <i>C4A</i> , <i>CSMD1</i> , and <i>Alu</i> at 8 different annealing temperatures.	108
Figure 4.2	The amplification curves of each gene's MethyLight™ serial dilution qPCR assay and the respective standard curves.	109
Figure 4.3	The amplification curves of each gene's MethyLight™ qPCR assay at 8 different percentages of methylated DNA template.	110
Figure 4.4	1D plot for <i>C4A</i> and <i>CSMD1</i> ddPCR copy number assay in both FAM and VIC channels, across eight different annealing temperatures.	112

Figure 4.5	1D plot for <i>C4A</i> ddPCR copy number assay in FAM channel using different combinations of reagent and DNA template concentrations, and different method of DNA template digestion.	113
Figure 4.6	Concentration and copy number values of <i>C4A</i> calculated from ddPCR reactions using enzymatically digested DNA at different combination of reagent concentrations.	114
Figure 4.7	1D plots and copy number calculated from ddPCR reactions using DNA template that was either digested during or prior to the mixing of ddPCR reaction components.	115
Figure 4.8	Differences in plasma C3 and C4 levels between groups.	116
Figure 4.9	Proportion of subjects with normal and elevated CRP in schizophrenia and control groups.	117
Figure 4.10	Distribution of plasma C3 and C4 levels at different CRP levels.	117
Figure 4.11	Box and whisker plot of plasma C4 levels Malay patients, Malay healthy controls, Chinese patients, and Chinese healthy controls.	119
Figure 4.12	Box plot showing the distribution of percentage of methylated reference (PMR) values for <i>C4A</i> between schizophrenia patients (SZ) and healthy controls (HC).	120
Figure 4.13	Frequency of three <i>C4A</i> CNV types among schizophrenia patients (SZ) and healthy controls (HC).	122
Figure 4.14	Correlation between plasma C4 levels and <i>C4A</i> PMR values, and plasma C4 levels and <i>C4A</i> copy number.	124
Figure 4.15	Box plot showing the distribution of percentage of methylated reference (PMR) values for <i>CSMD1</i> between schizophrenia patients and healthy controls.	127
Figure 4.16	Box plot showing the pairwise comparison of PMR values for <i>CSMD1</i> between Malay and Chinese patients, and between Malay and Chinese healthy controls.	129
Figure 4.17	The electropherogram of the RNA ladder and one of the RNA samples as produced by the QIAxcel Advanced system (QIAGEN, Germany).	131

Figure 4.18	Amplification curves and melt peak graphs for <i>CSMD1</i> , <i>ACTB</i> , and <i>GAPDH</i> .	132
Figure 4.19	The amplification and standard curves for each gene, from serial dilution of a random cDNA sample. The qPCR was performed at annealing temperature of 60°C.	133
Figure 4.20	The amplification and standard curves for each gene, from serial dilution of a random cDNA sample. The qPCR was performed at annealing temperature of 55°C.	134
Figure 4.21	The amplification and standard curves for each gene, from serial dilution of a random cDNA sample. The qPCR was performed at annealing temperature of 57°C.	135



LIST OF ABBREVIATIONS / SYMBOLS

5-HT2A	Serotonin 2A
<i>ACTB</i>	Beta actin (gene)
α 7nAChR	α 7 nicotinic acethyl choline Receptor
<i>BDNF</i>	Brain-derived neurotrophic factor (gene)
C4	Complement 4
C4A	Complement 4A (protein), a C4 isomer
<i>C4A</i>	Complement 4A (gene)
C4a	A subunit of complement C4 protein
C4B	Complement 4B (protein), a C4 isomer
<i>C4B</i>	Complement 4B (gene)
C4b	A subunit of complement C4 protein
cDNA	Complementary DNA
CGI	Clinical Global Impression scale
CNS	Central nervous system
CNV	Copy number variation
<i>COMT</i>	Catechol-O-methyltransferase (gene)
COX-2	Cyclooxygenase-2
CpG	Cytosine-phosphate-guanine
CSF	Cerebrospinal fluid
CSMD1	CUB and sushi multiple domains 1 (protein)
<i>CSMD1</i>	CUB and sushi multiple domains 1 (human gene)
<i>Csmd1</i>	CUB and sushi multiple domains 1 (mouse gene)
<i>CYP21</i>	Steroid 21-hydroxylase (gene)
D1	Dopamine 1 (receptor)
D2	Dopamine 2 (receptor)
DAF	Decay accelerating factor
ddPCR	Droplet digital polymerase chain reaction
<i>DISC1</i>	Disrupted in schizophrenia 1 (gene)
DMP	Differentially methylated position
DNA	Deoxyribonucleic acid
<i>DTNBP1</i>	Dystrobrevin binding protein 1 (gene)
ECT	Electroconvulsive therapy
EPS	Extrapyramidal symptoms
EWAS	Epigenome-wide association study
FGA	First-generation antipsychotic
GABA	Gamma-aminobutyric acid
<i>GAPDH</i>	Glyceraldehyde-3-phosphate dehydrogenase (gene)

GO	Gene ontology
GWAS	Genome-wide association study
HERV-K	Human endogenous retrovirus K
IDO	Indoleamine 2,3-deoxygenase
IFN	Interferon
IL	Interleukin
IQR	Interquartile range
KMO	Kynurenine monooxygenase
KYNA	Kynurenic acid
MAC	Membrane attack complex
MAM	Methylazoxymethanol acetate
MASP1	MBL-associated serine protease 1
MASP2	MBL-associated serine protease 2
MBL	Mannose-binding lectin
Mbp	Million base pairs
MHC	Major histocompatibility complex
MIA	Maternal immune activation
miRNA	MicroRNA
NMDA	N-methyl-D-aspartate
<i>NRG1</i>	Neuregulin 1 (gene)
<i>NRXN1</i>	Neurexin 1 (gene)
PAMP	Pathogen-associated molecular pattern
PANSS	Positive and negative syndrome scale
PFC	Prefrontal cortex
PMR	Percentage of methylated reference
Poly I:C	Polyinosinic:polycytidylic acid
PRR	Pattern recognition receptor
qPCR	Quantitative polymerase chain reaction
QT interval	The interval between Q and T peaks on an echocardiogram
<i>RELN</i>	Reelin (gene)
RM	Ringgit Malaysia
RNA	Ribonucleic acid
<i>RP</i>	Serine/threonine kinase 19 gene (old name)
r_s	Spearman correlation coefficient
RT-qPCR	Reverse transcription quantitative polymerase chain reaction
SGA	Second-generation antipsychotic
sRNA	Small RNA
SNP	Single nucleotide polymorphism
<i>STK19</i>	Serine/threonine kinase 19 (gene)
TDO	Tryptophan 2,3-deoxygenase
TGF- β	Transforming growth factor β

TMS	Transcranial magnetic stimulation
TNF- α	Tumour necrosis factor α
<i>TNX</i>	Tenascin-X (gene)



CHAPTER ONE

INTRODUCTION

1.1 BACKGROUND OF THE STUDY

Schizophrenia is a chronic and incapacitating mental illness, with 0.64% of the world population being at risk of developing at some point in their life (Moreno-Kustner, Martin, & Pastor, 2018). In 2019, there were estimated over 23.6 million people living with schizophrenia, or around 0.31% of the world population (Global Burden of Disease 2019 Mental Disorders Collaborators, 2022). Despite the relatively low prevalence, schizophrenia causes significant disease burden. It contributes to 12.7 million years (1.5% of total) of life lived with disability worldwide. Economy-wise, developed countries lost between 0.02% to 1.65% of their gross domestic product to schizophrenia (Chong et al., 2016). Schizophrenia onset is during late teens to early adulthood, costing patients their productive years and their futures. In Malaysia, schizophrenia was estimated to cost around RM 428 million in economic burden in year 2015. This figure included all treatment related cost, as well as costs due to absenteeism and unemployment (Teoh et al., 2017). Schizophrenia patients also have lower life expectancy than the general population (Hjorthoj, Sturup, McGrath, & Nordentoft, 2017). This could partly be because they are at higher risk of co-morbidities, substance abuse, violence, and suicide (Subramaniam et al., 2021).

Schizophrenia has complex clinical presentations and high heterogeneity among patients. There is a wide spectrum of signs and symptoms, usually grouped into the positive, negative, and cognitive domains. The contrasting nature of positive and negative symptoms suggests the involvement of different pathologies. Despite better effectiveness and side effect profiles in the newer generations of antipsychotics, the currently available agents do not have significant impact in treating the negative and cognitive symptoms such as lack of motivation, reduced emotional range, memory problems and deficit in executive functions (Haddad & Correll, 2018). While not as prominent as the positive symptoms, the negative and cognitive symptoms are equally as disruptive and disabling (Carbon & Correll, 2014). Therefore, it is important to